Prevalence and risk factors of erectile dysfunction in COVID-19 patients: a systematic review and meta-analysis

Abstract

Purpose Studies have found that erectile dysfunction (ED) may be a short-term or long-term complication in coronavirus disease 2019 (COVID-19) patients, but no relevant studies have completed a pooled analysis of this claim. The purpose of the review was to comprehensively search the relevant literature, summarize the prevalence of ED in COVID-19 patients, assess risk factors for its development, and explore the effect of the COVID-19 infection on erectile function. Methods Medline, Embase, and the Cochrane Library was performed from database inception until April 14, 2022. Heterogeneity was analyzed by χ 2 tests and I 2 was used as a quantitative test of heterogeneity. Subgroup analyses, meta-regression, and sensitivity analyses were used to analyze sources of heterogeneity. Results Our review included 8 studies, 4 of which functioned as a control group. There were 250,606 COVID-19 patients (mean age: 31–47.1 years, sample size: 23–246,990). The control group consisted of 10,844,200 individuals (mean age: 32.76–42.4 years, sample size 75–10,836,663). The prevalence of ED was 33% (95% CI 18–47%, I 2 = 99.48%) in COVID-19 patients. The prevalence of ED based on the international coding of diseases (ICD-10) was 9% (95% CI 2–19%), which was significantly lower than the prevalence of ED diagnosed based on the International Index of Erectile Function (IIEF-5) (46%, 95% CI 22–71%, I 2 = 96.72%). The pooling prevalence of ED was 50% (95% CI 34–67%, I 2 = 81.54%) for articles published in 2021, significantly higher than that for articles published in 2022 (17%, 95% CI 7–30%, I 2 = 99.55%). The relative risk of developing ED was 2.64 times in COVID-19 patients higher than in non-COVID-19 patients (RR: 2.64, 95% CI 1.01–6.88). The GRADE-pro score showed that the mean incidence of ED events in COVID-19 patients was 1,333/50,606 (2.6%) compared with 52,937/844,200 (0.4%) in controls; the absolute impact of COVID-19 on ED was 656/100,000 (ranging from 4/100,000 to 2352/100,000). Anxiety (OR: 1.13, 95% CI 1.03–1.26, I 2 = 0.0%) in COVID-19 patients was a risk factor for ED. Conclusion COVID-19 patients have a high risk and prevalence of ED, mainly driven by anxiety. Attention should be paid to patient’s erectile functioning when treating COVID-19. Supplementary Information The online version contains supplementary material available at 10.1007/s40618-022-01945-w.

Evaluating male sexual function and reproductive health during Omicron outbreak in China

“…SARS-CoV-2 viral infections not only causes respiratory damage, but may also have serious effects on the male patients' reproductive system which regulate many physiological processes. Even though it appears that erectile function deteriorates after COVID-19 infection, the function tends to improve over time 18 Patients with COVID-19 have a high risk and prevalence of ED, which may be driven primarily by anxiety, and attention should be paid to patients' erectile function when treating COVID-19 19 . Some researchers have also characterized the histopathology of tissue from patients who recovered from symptomatic COVID-19 infection, nding that the COVID-19 virus is present in the penis long after the initial infection in human 20 .…”

Evaluating male sexual function and reproductive health during Omicron outbreak in China: A cross-sectional study

“…Some researchers have also characterized the histopathology of tissue from patients who recovered from symptomatic COVID-19 infection, finding that the COVID-19 virus is present in the penis long after the initial infection in human [28]. Interestingly, an article suggested that PDE5 inhibitors, therapeutic agents for erectile function, may target potential targets of COVID-19 due to their anti-inflammatory, antioxidant, immune response modulating and anti-apoptotic properties[29] Meanwhile, a cross-sectional study showed that COVID-19 vaccination did not affect male sexual function, including erectile function [30]. In addition to biological and mental health factors, one study demonstrated that COVID-19 may also have a unique detrimental effect on men's health and erectile function through health care access mechanisms [31].…”

Investigating in-vitro functionality and in-vivo taste assessment of eco-friendly Tadalafil Pastilles

“…Its occurrence increases drastically from about 6 % in the age group 20–29 years to 50–70 % in the age group 40–79 years. Its rate is projected to increase significantly to over 320 million by 2025 [ [3] , [4] , [5] ]. India is the feebleness capital of the world because of the high infection rate in the male reproductive system and more males [ [6] , [7] , [8] , [9] ].…”